Skip to main content
SpringerLink
Log in

Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma

  • Correspondence
  • Published:

From Nature Medicine

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Locke, F. L. et al. New Engl. J. Med. 386, 640–654 (2022).

    Article  CAS  Google Scholar 

  2. Kamdar, M. et al. Lancet 399, 2294–2308 (2022).

    Article  CAS  Google Scholar 

  3. Jacobson, C. A. et al. J. Clin. Oncol. 38, 3095–3106 (2020).

    Article  CAS  Google Scholar 

  4. Bethge, W. A. et al. Blood 140, 349–358 (2022).

    CAS  Google Scholar 

  5. Jain, M. D. et al. Blood 137, 2621–2633 (2021).

    Article  CAS  Google Scholar 

  6. Shadman, M. et al. Blood 139, 1330–1339 (2022).

    Article  CAS  Google Scholar 

  7. Armand, P. et al. Br. J. Haematol. 160, 608–617 (2013).

    Article  Google Scholar 

  8. Kurtz, D. M. et al. J. Clin. Oncol. 36, 2845–2853 (2018).

    Article  CAS  Google Scholar 

  9. Wang, Y. et al. J Clin. Oncol. 37, 1819–1827 (2019).

    Article  CAS  Google Scholar 

  10. Lin, J. K. et al. J. Clin. Oncol. 37, 2105–2119 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Edward R. Scheffer Cliff, Reid W. Merryman.

Authors and Affiliations

  1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Edward R. Scheffer Cliff, Reid W. Merryman, Philippe Armand & Caron A. Jacobson

  2. Program on Regulation, Therapeutics and Law, Brigham and Women’s Hospital, Boston, MA, USA

    Edward R. Scheffer Cliff

  3. Harvard Medical School, Boston, MA, USA

    Edward R. Scheffer Cliff, Reid W. Merryman, Philippe Armand & Caron A. Jacobson

Authors
  1. Edward R. Scheffer Cliff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reid W. Merryman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philippe Armand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Caron A. Jacobson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward R. Scheffer Cliff.

Ethics declarations

Competing interests

R.W.M has served as a consultant for Genmab/AbbVie, Adaptive Biotechnologies, Bristol-Myers Squibb, Intellia and Epizyme and received research funding (institutional) from Merck, Bristol-Myers Squibb, Genentech/Roche and Genmab. P.A. has served as a consultant for Merck, Bristol-Myers Squibb, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene and MorphoSys; received research funding (institutional) from Merck, Bristol-Myers Squibb, Affimed, Adaptive, Roche, Tensha, Otsuka, Sigma-Tau, Genentech and IGM; and received honoraria from Bristol-Myers Squibb and Merck. C.A.J. has served as a consultant for Kite, Novartis, Pfizer, Humanigen, Precision Bioscience, Bayer and Celgene and has received research funding from Pfizer and Kite.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cliff, E.R.S., Merryman, R.W., Armand, P. et al. Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma. Nat Med 28, 2458–2459 (2022). https://doi.org/10.1038/s41591-022-02067-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-02067-9

  • Springer Nature America, Inc.

Search

Navigation